WEBULL
News
APLIF
0.023
NaN%
--
Appili Therapeutics Raises C$177,500 in First Tranche of Private Placement
TipRanks · 19h ago
Weekly Report: what happened at APLIF last week (1208-1212)?
Weekly Report · 3d ago
Weekly Report: what happened at APLIF last week (1201-1205)?
Weekly Report · 12/08 10:05
Weekly Report: what happened at APLIF last week (1124-1128)?
Weekly Report · 12/01 10:01
Weekly Report: what happened at APLIF last week (1117-1121)?
Weekly Report · 11/24 10:05
Weekly Report: what happened at APLIF last week (1110-1114)?
Weekly Report · 11/17 10:05
Appili Therapeutics GAAP EPS of -$0.01
Seeking Alpha · 11/14 18:34
Appili Therapeutics Inc. GAAP EPS of -$0.01
Seeking Alpha · 11/14 16:26
Appili Therapeutics Q2 Sales Increase
NASDAQ · 11/13 23:57
Appili Therapeutics Reports Strong Q2 Results and Secures Major Funding for Infectious Disease Programs
TipRanks · 11/13 23:16
Weekly Report: what happened at APLIF last week (1103-1107)?
Weekly Report · 11/10 10:03
Appili Therapeutics Launches C$750,000 Private Placement to Boost Drug Development
TipRanks · 11/05 13:16
Appili Therapeutics prices 30M units at $0.025 in private placement
TipRanks · 11/05 12:50
Weekly Report: what happened at APLIF last week (1027-1031)?
Weekly Report · 11/03 10:03
Weekly Report: what happened at APLIF last week (1020-1024)?
Weekly Report · 10/27 10:06
Appili Therapeutics to Showcase Biodefense Innovations at BARDA Symposium
TipRanks · 10/22 11:51
Appili Therapeutics to Attend BARDA Innovation Symposium 2025
Barchart · 10/22 06:20
Weekly Report: what happened at APLIF last week (1013-1017)?
Weekly Report · 10/20 10:03
Weekly Report: what happened at APLIF last week (1006-1010)?
Weekly Report · 10/13 10:05
Weekly Report: what happened at APLIF last week (0929-1003)?
Weekly Report · 10/06 10:03
More
Webull provides a variety of real-time APLIF stock news. You can receive the latest news about Appili Ther through multiple platforms. This information may help you make smarter investment decisions.
About APLIF
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.